Skip to content
Open access

Biocompatible chitosan-coated polydatin@ZIF-8 MOF nanostructures: synthesis, drug delivery and enhanced antibacterial properties

Aug 2026 · RSC Advances · Vol 16, pp. 46808 - 46826 · 2 citations · ⚡ 1 influential · 72 references
Medicine

TL;DR

PD@ZIF-8/CS is a strong and pH-sensitive nanoplatform that can selectively release the drug in the acidic microenvironment of infection sites, suggesting its potential utility as an antibacterial nanoplatform, pending further biological validation.

Abstract

Zeolitic imidazolate framework-8 (ZIF-8) is a promising nanocarrier for drug delivery due to its tunable porosity, biocompatibility, and pH sensitivity. In this study, a one-pot room-temperature synthesis strategy was developed to encapsulate polydatin (PD) within ZIF-8 (PD@ZIF-8), followed by chitosan (CS) coating (PD@ZIF-8/CS) for improved stability and sustained release of this drug delivery system. FTIR, UV-vis, XRD, DLS and TGA characterization confirmed the successful synthesis of PD@ZIF-8/CS. SEM micrographs revealed the rhombic dodecahedral particles (85.2 nm) of ZIF-8, slightly roughened polyhedral particles (115.4 nm) of PD@ZIF-8 and aggregated particles (294.8 nm) of PD@ZIF-8/CS, confirming CS shell formation. DLS analysis showed hydrodynamic diameters of 99.3 ± 2.1 nm, 112.8 ± 3.4 nm, and 251.7 ± 4.6 nm for ZIF-8, PD@ZIF-8 and PD@ZIF-8/CS, respectively, with the zeta potential shifting from +12.6 to −3.9 mV after CS coating. The PD@ZIF-8 system achieved an outstanding drug-loading efficiency (91.34%) and exhibited pH-dependent release, reaching 92.5% release at pH 5.0 and 37 °C within 72 h, while the CS coating reduced the burst release by ∼35% and prolonged t0 from 18.4 h to 38.6 h, following the Korsmeyer–Peppas model (R2 = 0.991). The PD@ZIF-8/CS composite displayed potent antibacterial activity (inhibition zones: 24.6 ± 0.4 mm for S. aureus and 21.2 ± 0.3 mm for E. coli; MIC: 6.25 µg mL−1), demonstrating a synergistic effect of PD, ZIF-8 and CS. These findings indicate that PD@ZIF-8/CS is a strong and pH-sensitive nanoplatform that can selectively release the drug in the acidic microenvironment of infection sites, suggesting its potential utility as an antibacterial nanoplatform, pending further biological validation.

Read PDF

Similar papers

Open access Aug 2026

Electrophoretic Deposition and Characterization of Multicomponent Chitosan/Eudragit or Poly(4-vinylpyridine) Coatings Incorporating Mesoporous Bioactive Glass and Silver Nanoparticles on Ti-13Nb-13Zr Alloy.

In this study, multifunctional composite coatings based on chitosan (CS), mesoporous bioactive glass nanoparticles (MBGNPs), and silver nanoparticles (AgNPs) were successfully deposited on Ti-13Nb-13Zr alloy by electrophoretic deposition (EPD). Two coating systems containing Eudragit E100 (EE100) or poly(4-vinylpyridin...

L. Pawlowski, Yi-Xin Liu, Chen-Ying Su et al. · 0 citations
Open access Sep 2026

Design and optimization of Pt@ZIF-8 nanostructures via QbD approach: structural characterization and cytotoxic insights

Platinum nanoparticles (Pt NPs) exhibit inherent anticancer properties; however, their therapeutic application is limited by poor colloidal stability, ineffective cellular uptake, and inconsistent formulation reproducibility. While zeolitic imidazolate framework-8 (ZIF-8) has shown promise as a pH-responsive nanocarrie...

Dhara Pandey, Sarvesh Rahate, Kunal M. Gokhale · 0 citations
Open access Aug 2026

FORMULATION AND QBD-BASED OPTIMIZATION OF CHITOSAN-COATED NANOSTRUCTURED LIPID CARRIERS FOR ENHANCED DRUG DELIVERY OF AZILSARTAN MEDOXOMIL

Objective: Azilsartan medoxomil (AZM) is a Class II antihypertensive drug with poor aqueous solubility that limit its dissolution and oral performance. The aim of present investigation was to improve its dissolution properties by formulating chitosan-coated AZM NLCs (CH-NLCs) and optimizing using QbD approach. Methods:...

Jeyaprabha Ponnusamy, Saravanan Gopal · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.